PDT and BF-200 ALA: The therapy option for the treatment of Poikiloderma of Civatte

Dermatol Ther. 2018 Jul;31(4):e12648. doi: 10.1111/dth.12648. Epub 2018 Jul 17.

Abstract

Poikiloderma is a chronic skin condition affecting middle-age men and women that comprises cutaneous atrophy, telangiectasias, and changes in the pigmentation of the skin usually of mottled appearance (both hyper- and hypopigmentation). There is no specific medical treatment for Poikiloderma of Civatte (PC), but the use of photoprotector/sunscreen + SPF 50 to avoid prolonged sun exposure is highly recommended in these patients. Some authors recommend the use of topical corticoids in early stages; however, the results have not been satisfactory. Multiple topical (retinoids, dimethyl sulfoxide, or calcineurin inhibitors), systemic (cyclophosphamide), and physical (dermabrasion, phototherapy, and fractional photothermolysis) treatments have been described with unequal and inconsistent responses or unsatisfactory. This report underlies the combination of BF-200 ALA and photodynamic therapy (PDT) with positive results at the clinical level: significant improvement of pigmentary changes and telangiectasias after two PDT sessions.

Keywords: Poikiloderma of Civatte; photodynamic therapy.

Publication types

  • Case Reports

MeSH terms

  • Aminolevulinic Acid / administration & dosage
  • Aminolevulinic Acid / analogs & derivatives*
  • Atrophy
  • Female
  • Humans
  • Middle Aged
  • Photochemotherapy / methods*
  • Photosensitizing Agents / administration & dosage*
  • Pigmentation Disorders / diagnosis
  • Pigmentation Disorders / drug therapy*
  • Pigmentation Disorders / physiopathology
  • Remission Induction
  • Skin / drug effects*
  • Skin / pathology
  • Skin / physiopathology
  • Skin Pigmentation / drug effects*
  • Telangiectasis / diagnosis
  • Telangiectasis / drug therapy*
  • Treatment Outcome

Substances

  • BF-200 ALA
  • Photosensitizing Agents
  • Aminolevulinic Acid